glucagon-like peptide-1 news

Medicaid covers GLP-1 weight-loss drugs in just 13 states

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Newsweek on MSN · 5h

Map Shows States Where Weight Loss Drugs are Most Popular

Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit at the other end of the spectrum, a report has revealed. Glucagon-like peptide-1 (GLP-1) receptor analogs are drugs that mimic fullness hormone GLP-1 and have been shown to reduce appetite,

U.S. News & World Report · 10h

Medicaid Covers GLP-1 Meds for Obesity in Just 13 States

Expanding Medicaid coverage of these drugs could increase access for the almost 40% of adults and 26% of children with obesity in Medicaid,” wrote the research team led by se

Axios Vitals on MSN · 12h

States slow to cover GLP-1s for weight loss

Axios Visuals Budget pressures have kept all but 13 states from covering GLP-1 drugs for weight loss through their Medicaid programs, a new report from KFF shows. Why it matters: The restrictive policies add to equity concerns around the blockbuster drugs,

Medical Xpress22h

Medicaid covers GLP-1 meds for obesity in just 13 states, analysis finds

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

AOL15h

4 Ways to Prevent Muscle Loss on Ozempic & Other Weight Loss GLP-1 Medications

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor ...

2minutemedicine.com7d

Glucagon-like peptide-1 receptor agonists may impact outcomes of endoscopy

The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...

Guidance issued for safe use of GLP-1 RAs in the perioperative period

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

Neurology Advisor1d

Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity

For adolescents with obesity, GLP1-RA treatment is associated with a reduced risk for suicidal ideation or attempts.

2minutemedicine.com5d

Glucagon-like peptide 1 receptor agonists may decrease rates of inflammatory bowel disease flares

The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...

GEN4d

StockWatch: Investors Hammer Lilly as GLP-1 Sales Miss Forecasts

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...

EurekAlert!19d

Ozempic is one of several medications, called glucagon-like peptide-1 receptor agonists or GLP-1 RAs, that are prescribed to treat diabetes, obesity, and other weight-related medical conditions.

The Motley Fool10d

This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)

Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication to Ozempic and Wegovy. Per a phase 3 trial, Rybelsus was found to reduce cardiovascular risk among patients with ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results